Upgrade to SI Premium - Free Trial

Outlook for sabizabulin Unchanged - Oppenheimer Defends Veru (VERU) Despite Weakness

August 31, 2022 9:15 AM
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $36.00 price target on Veru, Inc. (NASDAQ: VERU), following independent publication ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments